Tango Therapeutics (TNGX) to Release Earnings on Thursday

Tango Therapeutics (NASDAQ:TNGX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics Stock Performance

NASDAQ TNGX opened at $12.41 on Thursday. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $13.48. The company has a fifty day moving average of $10.88 and a 200-day moving average of $8.95. The company has a market capitalization of $1.67 billion, a P/E ratio of -13.34 and a beta of 1.75.

Analysts Set New Price Targets

TNGX has been the topic of several recent research reports. Piper Sandler increased their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Monday, October 27th. Wolfe Research started coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Stifel Nicolaus began coverage on shares of Tango Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 18,452 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $226,221.52. Following the completion of the sale, the insider directly owned 187,218 shares in the company, valued at approximately $2,295,292.68. This trade represents a 8.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniella Beckman sold 10,317 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the completion of the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 59,288 shares of company stock valued at $726,871 over the last ninety days. 7.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd boosted its position in Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares during the period. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Legal & General Group Plc grew its holdings in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Tango Therapeutics by 44.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after buying an additional 2,907 shares during the last quarter. Finally, Northeast Financial Consultants Inc purchased a new position in shares of Tango Therapeutics during the second quarter worth approximately $51,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.